The median progression free survival of advanced non-small cell lung cancer (NSCLC) patients with EGFR-sensitive mutations treated with first-generation EGFR-TKI is about 10 to 12 months.[5–7] This patient had a shorter Progression-free survival after gefitinib treatment (8 months) than the reported data. This evidence concerns the gene EGFR and non-small cell lung carcinoma.